Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 13/20 | 0.68 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.68 |
| ▸ | DHCR7 | Q9UBM7 | 2/20 | 0.57 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verilopam SCHEMBL11385505 | 0.99 | ABCB1 (0.67) | ABCB1ABCG2DHCR7CYP19A1CYP3A4 | |
| Verilopam SCHEMBL121615 | 0.99 | ABCB1 (0.67) | ABCB1ABCG2DHCR7CYP19A1CYP3A4 | |
| Verilopam SCHEMBL29658195 | 0.99 | ABCB1 (0.67) | ABCB1ABCG2DHCR7CYP19A1CYP3A4 | |
| SCHEMBL2771882 | 0.93 | ABCB1 (0.78) | ABCB1ABCG2DHCR7CYP3A4KMT2A | |
| Hydrochloric Acid SCHEMBL10661663 | 0.92 | ABCB1 (0.76) | ABCB1ABCG2DHCR7CYP3A4KMT2A | |
| SCHEMBL8790535 | 0.85 | ABCB1 (0.68) | ABCB1ABCG2DHCR7KMT2A | |
| SCHEMBL3143129 | 0.85 | KMT2A (0.64) | ABCB1ABCG2KMT2A | |
| SCHEMBL8790386 | 0.85 | ABCB1 (0.64) | ABCB1ABCG2DHCR7CYP19A1CYP3A4 | |
| SCHEMBL14330769 | 0.85 | DHCR7 (0.79) | ABCB1ABCG2DHCR7 | |
| SCHEMBL17664977 | 0.85 | DHCR7 (0.79) | ABCB1ABCG2DHCR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-11235128-B2 | Devices for delivering a chemical denervation agent and methods of use | MEDTRONIC HOLDING COMPANY SÀRL (CH) | 2022-02-01 | — | — | US | disclosed |
| EP-3943501-A1 | SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES | Halozyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-10588983-B2 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases | HALOZYME, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20200069920-A1 | DEVICES FOR DELIVERING A CHEMICAL DENERVATION AGENT AND METHODS OF USE | MEDTRONIC EUROPE SÀRL (CH) | 2020-03-05 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-4282146-A | Preparation of 1,2,4,5-tetrahydro-7-alkoxy-(and 7,8-dialkoxy)-3H,3-benzazepines and 3-substituted derivatives thereof from the corresponding phenethylamines | PENNWALT CORPORATION (US) | 1981-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | ABCB1 1312/4885ABCG2 413/4885DHCR7 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.